Medicinova Stock Price, News & Analysis

MediciNova (NASDAQ: MNOV) announced that MN-166 (ibudilast) is recognized as a promising treatment for alcohol use disorder (AUD) in a journal publication. The article, co-authored with Dr. Lara Ray, outlines that MN-166 is effective in reducing alcohol intake and cravings, improving mood, and mitigating the effects of alcohol. With 14.5 million individuals in the U.S. suffering from AUD, and only a small percentage receiving treatment, MN-166's potential could address this significant medical need. The drug is in late-stage development for multiple conditions.

MediciNova, a biopharmaceutical company, announced it received a new patent from the Korean Intellectual Property Office for MN-001 (tipelukast) aimed at treating hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. The patent is expected to expire no earlier than July 2034 and covers various dosages and administration forms. The company notes promising results from its Phase 2 trial with MN-001, showing a significant reduction in serum triglycerides. MediciNova continues to develop innovative therapies for various diseases.

MediciNova, Inc. (NASDAQ: MNOV) has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent concerning MN-001 (tipelukast) and its metabolite MN-002, which target hepatic ballooning. This patent is anticipated to be granted by January 2035 and covers various oral administration forms. The Chief Medical Officer highlighted MN-001's efficacy in improving NASH pathology in animal models. MediciNova is focused on developing therapies for inflammatory and fibrotic diseases, currently advancing multiple clinical programs, including MN-166 for ALS.

MediciNova, a biopharmaceutical company trading as MNOV, announced receiving a Notice of Intention to Grant from the European Patent Office for MN-166 (ibudilast), targeting alcohol use disorder (AUD). This patent, expected to expire no earlier than May 2037, covers various dosage regimens and combination therapies. Clinical trials have shown MN-166 significantly reduces heavy drinking and alcohol cravings. The company aims to meet the high unmet medical need for AUD treatments, with ongoing studies funded by the NIH and collaborations with UCLA.

MediciNova, Inc. announced receiving a Notice of Intention to Grant from the European Patent Office for MN-001 (tipelukast) and MN-002 related to inhibiting hepatic ballooning, with expected patent expiration in January 2035. The claims cover oral forms and various dosages. MN-001 has shown promising results in improving NASH pathology in animal models, with significant NAFLD activity score improvements. The company is focused on developing therapies for fibrotic and neurodegenerative diseases, with MN-166 also in late-stage trials for ALS and MS.

MediciNova, traded as MNOV on NASDAQ, announced a Notice of Allowance from the U.S. Patent Office for a patent covering the combination of MN-166 (ibudilast) and riluzole for treating amyotrophic lateral sclerosis (ALS). This patent is expected to expire no earlier than November 2035 and includes various dosage forms. Chief Medical Officer Kazuko Matsuda stated that this patent will enhance the company's ALS patent portfolio. ALS affects approximately 16,000 patients in the U.S. annually, highlighting the potential market for MN-166.

MediciNova, Inc. (NASDAQ: MNOV) announced the presentation of its ongoing Phase 2b/3 clinical trial of MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS) at the 32nd International Symposium on ALS/MND, held virtually from December 7-10, 2021. Dr. Malath Makhay detailed the trial's objectives, design, and recent adaptations to enhance patient participation. The trial aims to enroll 230 patients across 30 sites, with the primary endpoint being the change in ALSFRS-R score at 12 months. CEO Dr. Yuichi Iwaki highlighted the trial's importance and the addition of new recruitment sites.

MediciNova (NASDAQ:MNOV) has announced promising results from a study presented by Dr. Justin Lathia at the Society for Neuro-Oncology's annual meeting regarding the efficacy of MN-166 (ibudilast) in combination with PD-1 inhibitors for treating glioblastoma (GBM). The study demonstrated a median survival increase from 28 days with PD-1 alone to 66 days when combined with MN-166, a significant finding (p<0.001). MediciNova aims to progress to clinical trials based on these encouraging outcomes, underscoring the potential of MN-166 to enhance GBM treatment.

MediciNova, Inc. (NASDAQ:MNOV) announced a study by Dr. Masatsune Ogura, revealing MN-001 (tipelukast) reduces triglyceride (TG) synthesis in liver cells. Presented at The Liver Meeting 2021, findings indicate that MN-001 inhibits TG synthesis by suppressing CD36 expression, a fatty acid transporter, in HepG2 cells. Compared to untreated cells, TG synthesis increased significantly with arachidonic acid and LXR agonist T0901317. MN-001 shows potential in addressing nonalcoholic steatohepatitis (NASH) by improving lipid metabolism.